" class="no-js "lang="en-US"> Kelly Pokuta - Medtech Alert
Monday, September 29, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Kelly Pokuta

Kelly Pokuta

About Kelly Pokuta

Strategic, entrepreneurial, innovative, and highly experienced healthcare professional with extensive expertise in specialty pharmacy, pharmacy benefit management, health plans/managed care, pharmaceutical industry, and clinical research/practice.

Related Story

Industry News

 Prime Therapeutics and Pear Therapeutics Announce First Comprehensive Value-based Agreement for Prescription Digital Therapeutics reSET® and reSET-O® for the Treatment of Substance and Opioid Use Disorders | Pharmtech Focus

Prime Therapeutics and Pear Therapeutics Announce First Comprehensive Value-based Agreement for Prescription Digital Therapeutics reSET® and reSET-O® for the Treatment of Substance and Opioid Use Disorders

September 30 2021

More than 20 million Americans struggle with drug addiction while only 10-20% receive treatment. Prime Therapeutics […]